Rabies

This phase 3 trial tests a freeze-dried rabies vaccine in healthy Chinese volunteers aged 10 to 60. The study compares the new vaccine's ability to trigger protective antibodies and its safety against an existing rabies vaccine. Rabies is nearly always fatal once symptoms appear,…

This early-stage trial tested two new vaccines—one for yellow fever and one for rabies—in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Participants received different doses or a placebo to help find …

This study tested a new rabies vaccine given in different schedules after exposure. It involved 2,040 healthy people aged 10-60. The goal was to see if the vaccine triggers a strong immune response and is safe compared to a standard vaccine.

This Phase 3 trial tested a new rabies vaccine called VRVg-2 in 403 healthy volunteers in Thailand. The study compared two different vaccination schedules and also looked at combining the vaccine with rabies antibodies (immunoglobulins). The goal was to see if the new vaccine pro…

This early-stage trial tested the safety of a new rabies vaccine in 80 healthy people aged 10 to 60. Participants received one of two different vaccination schedules. Researchers monitored for side effects for up to 6 months. The goal was to see if the vaccine is safe enough to m…

This trial tests whether a two-visit rabies vaccine schedule (with two small doses on day 0 and day 7) is as safe and effective as the standard three-visit schedule (with one dose on days 0, 7, and 28) in healthy adults. The goal is to see if both schedules produce a strong immun…

This study tested a new medicine called SYN023 to prevent rabies in people who were bitten or scratched by animals like dogs or bats. About 448 adults with different levels of rabies risk received either SYN023 or the standard rabies immune globulin, along with the rabies vaccine…

This study looked at whether a rabies vaccine (RabAvert) can be given just under the skin instead of into a muscle. Researchers tested it in 130 adults, some who had never been vaccinated and some who had. The goal was to see if the skin shot triggers enough protection and is saf…

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 1708 healthy children and adults in Thailand. The goal was to see if it works as well as two existing rabies vaccines when given before exposure to the virus. Participants received a series of shots, and some got a booste…

This study tested a new combination of lab-made antibodies (SYN023) given alongside the rabies vaccine to healthy children under 18. The goal was to see if it is safe and how well it works compared to the standard treatment. A total of 108 children received either a low or high d…

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 201 healthy adults in Thailand. Participants received the vaccine along with rabies antibodies, mimicking post-exposure treatment. The study measured immune response and safety, finding that the vaccine triggered protecti…

This phase 3 trial tested a new rabies vaccine (VRVg-2) in 640 healthy adults in France. Participants received the vaccine along with rabies immune globulin, mimicking a real post-exposure scenario. The study found that VRVg-2 produced protective antibody levels as effectively as…

This completed early-phase study looked at how healthy adults respond to the rabies vaccine when given alone or with an immune-boosting shot (rabies immune globulin). Thirty participants received different combinations of vaccine and immune globulin to compare antibody levels ove…

This completed study surveyed 214 Egyptian doctors—emergency physicians, general practitioners, and surgeons—to see how closely they follow official guidelines for rabies prevention after animal bites. Doctors answered 10 case-based questions, and their scores showed how well the…